PKD 2
MCID: PLY049
MIFTS: 15

Polycystic Kidney Disease 2, Autosomal Dominant (PKD 2) malady

Categories: Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Polycystic Kidney Disease 2, Autosomal Dominant

Aliases & Descriptions for Polycystic Kidney Disease 2, Autosomal Dominant:

Name: Polycystic Kidney Disease 2, Autosomal Dominant 24
Pkd 2 24

Classifications:



Summaries for Polycystic Kidney Disease 2, Autosomal Dominant

MalaCards based summary : Polycystic Kidney Disease 2, Autosomal Dominant, also known as pkd 2, is related to lymphoma. An important gene associated with Polycystic Kidney Disease 2, Autosomal Dominant is PKD2 (Polycystin 2, Transient Receptor Potential Cation Channel). The drugs Candesartan and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney.

Related Diseases for Polycystic Kidney Disease 2, Autosomal Dominant

Diseases in the Polycystic Kidney Disease family:

Polycystic Kidney Disease 2 Polycystic Kidney Disease, Adult Type I
Polycystic Kidney Disease 3 Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney Disease 1, Autosomal Dominant Polycystic Kidney Disease 2, Autosomal Dominant

Diseases related to Polycystic Kidney Disease 2, Autosomal Dominant via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 lymphoma 9.8

Symptoms & Phenotypes for Polycystic Kidney Disease 2, Autosomal Dominant

Drugs & Therapeutics for Polycystic Kidney Disease 2, Autosomal Dominant

Drugs for Polycystic Kidney Disease 2, Autosomal Dominant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Candesartan Approved Phase 4,Phase 2 139481-59-7 2541
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
3
Cilnidipine Approved Phase 4,Phase 2 132203-70-4 5282138
4
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
5
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
6
Angiotensin II Phase 4,Phase 3,Phase 2 68521-88-0, 11128-99-7 65143 172198
7
Candesartan cilexetil Phase 4,Phase 2 145040-37-5 2540
8 calcium channel blockers Phase 4,Phase 3,Phase 2
9 Adrenergic Agents Phase 4
10 Adrenergic Antagonists Phase 4
11 Adrenergic alpha-Antagonists Phase 4
12 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3
13 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
14 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2
15 Angiotensinogen Phase 4,Phase 3,Phase 2
16 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
18 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
19 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Antihypertensive Agents Phase 4,Phase 3,Phase 2
21 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
22 Calcium, Dietary Phase 4,Phase 3,Phase 2
23 Peripheral Nervous System Agents Phase 4,Phase 2
24
Curcumin Phase 4 458-37-7 969516
25 Analgesics Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Anti-Inflammatory Agents Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Antirheumatic Agents Phase 4
30
lanreotide Approved Phase 2, Phase 3 108736-35-2
31
Clonidine Approved Phase 3 4205-90-7 2803
32
Pravastatin Approved Phase 3 81093-37-0 54687
33
Minoxidil Approved Phase 3 38304-91-5 4201
34
Lisinopril Approved, Investigational Phase 3 83915-83-7 5362119
35
Hydrochlorothiazide Approved, Vet_approved Phase 3 58-93-5 3639
36
Telmisartan Approved, Investigational Phase 3 144701-48-4 65999
37
Hydralazine Approved Phase 3 86-54-4 3637
38
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
39
Diltiazem Approved Phase 3 42399-41-7 39186
40
Octreotide Approved, Investigational Phase 3,Phase 2 83150-76-9 383414 6400441
41
Tolvaptan Approved Phase 3,Phase 2 150683-30-0 216237
42
Somatostatin Approved Phase 3,Phase 2 38916-34-6, 51110-01-1 53481605
43
Benzocaine Approved Phase 2, Phase 3 1994-09-7, 94-09-7 2337
44 tannic acid Approved, Nutraceutical Phase 2, Phase 3
45
protease inhibitors Phase 3,Phase 2
46 HIV Protease Inhibitors Phase 3,Phase 2
47 Angiopeptin Phase 2, Phase 3
48 Liver Extracts Phase 2, Phase 3
49
Lactitol Phase 3 585-86-4 3871
50 diuretics Phase 3

Interventional clinical trials:

(show top 50) (show all 62)
id Name Status NCT ID Phase
1 CCB Safety Study in Treatment of Hypertension of ADPKD Unknown status NCT00541853 Phase 4
2 Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease Completed NCT00414440 Phase 4
3 Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD Recruiting NCT02494141 Phase 4
4 Sirolimus for Massive Polycystic Liver Unknown status NCT01680250 Phase 2, Phase 3
5 Open-Label Extension of LOCKCYST Trial Unknown status NCT00771888 Phase 2, Phase 3
6 A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] Completed NCT01022424 Phase 3
7 Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease Completed NCT02225860 Phase 2, Phase 3
8 Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00456365 Phase 3
9 Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00346918 Phase 3
10 Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study Completed NCT00309283 Phase 3
11 Effects of Somatostatin on ADPKD Heart Completed NCT02119013 Phase 2, Phase 3
12 Effects of Somatostatin on Liver in ADPKD Completed NCT02119052 Phase 2, Phase 3
13 HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A Completed NCT00283686 Phase 3
14 HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B Completed NCT01885559 Phase 3
15 Open-Label Tolvaptan Study in Subjects With ADPKD Completed NCT01214421 Phase 3
16 Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD Completed NCT00428948 Phase 3
17 Lanreotide as Treatment of Polycystic Livers Completed NCT00565097 Phase 2, Phase 3
18 Octreotide in Severe Polycystic Liver Disease Completed NCT00426153 Phase 2, Phase 3
19 Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease Recruiting NCT02055079 Phase 3
20 Lanreotide In Polycystic Kidney Disease Study Recruiting NCT02127437 Phase 3
21 Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease Active, not recruiting NCT02160145 Phase 3
22 Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency Active, not recruiting NCT01377246 Phase 3
23 Study of Lanreotide to Treat Polycystic Kidney Disease Active, not recruiting NCT01616927 Phase 3
24 Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Enrolling by invitation NCT02251275 Phase 3
25 Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency Terminated NCT01223755 Phase 2, Phase 3
26 Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy Terminated NCT00920309 Phase 2, Phase 3
27 Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study Unknown status NCT00571909 Phase 2
28 Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD) Unknown status NCT00890279 Phase 2
29 Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control Unknown status NCT01932450 Phase 2
30 Bosutinib For Autosomal Dominant Polycystic Kidney Disease Completed NCT01233869 Phase 2
31 Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00286156 Phase 1, Phase 2
32 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT01451827 Phase 2
33 Effect of the Aquaretic Tolvaptan on Nitric Oxide System Completed NCT02527863 Phase 2
34 Tolvaptan Open-Label Pilot Efficacy, Tolerability and Safety Study in ADPKD Completed NCT00413777 Phase 2
35 Short-Term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT01336972 Phase 2
36 Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety Completed NCT00491517 Phase 2
37 A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001] Completed NCT00841568 Phase 2
38 Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD Completed NCT01210560 Phase 2
39 Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease Completed NCT02140814 Phase 2
40 Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease Completed NCT02021110 Phase 2
41 Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease Recruiting NCT02656017 Phase 2
42 Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease Recruiting NCT02697617 Phase 2
43 Feasibility Study of Metformin Therapy in ADPKD Recruiting NCT02903511 Phase 2
44 A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Active, not recruiting NCT01559363 Phase 1, Phase 2
45 Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 Active, not recruiting NCT02616055 Phase 2
46 Pasireotide LAR in Severe Polycystic Liver Disease Active, not recruiting NCT01670110 Phase 2
47 The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease Completed NCT00410007
48 Clinical Implications of DNA Analysis on ADPKD Completed NCT02322385
49 Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00759369
50 Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease Completed NCT00598377

Search NIH Clinical Center for Polycystic Kidney Disease 2, Autosomal Dominant

Genetic Tests for Polycystic Kidney Disease 2, Autosomal Dominant

Genetic tests related to Polycystic Kidney Disease 2, Autosomal Dominant:

id Genetic test Affiliating Genes
1 Polycystic Kidney Disease 2, Autosomal Dominant 24 PKD2

Anatomical Context for Polycystic Kidney Disease 2, Autosomal Dominant

MalaCards organs/tissues related to Polycystic Kidney Disease 2, Autosomal Dominant:

39
Kidney

Publications for Polycystic Kidney Disease 2, Autosomal Dominant

Variations for Polycystic Kidney Disease 2, Autosomal Dominant

Expression for Polycystic Kidney Disease 2, Autosomal Dominant

Search GEO for disease gene expression data for Polycystic Kidney Disease 2, Autosomal Dominant.

Pathways for Polycystic Kidney Disease 2, Autosomal Dominant

GO Terms for Polycystic Kidney Disease 2, Autosomal Dominant

Sources for Polycystic Kidney Disease 2, Autosomal Dominant

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....